GSK Prunes The Pipeline To Make Way For The New
CEO Emma Walmsley has vowed to be more decisive when it comes to progressing drugs to late-stage development. The company terminated five programs, including several in respiratory disease to prioritize other assets and business development.
You may also be interested in...
The drug giant's strategy of divesting old assets continues apace with the $350m sale of the ciclesonide-based drugs Alvesco, Omnaris and Zetonna to the Swiss specialty pharma group.
GSK President R&D Hal Barron came to a big investor meeting with one bit of tangible news, a collaboration with consumer genetics leader 23andMe. Barron and CEO Emma Walmsley talked about the deal and Barron's California headquarters in a media briefing.
Appointments: Novartis And GSK Announce New R&D Heads, LNC Therapeutics Gets A New CEO, Plus Announcements From Zelluna and BC Platforms
This week's appointments include new R&D heads at Novartis and GSK, while LNC Therapeutics gets a new CEO, Plus announcements from Zelluna and BC Platforms.